Physician profile
Bruce L Buchsbaum
NPI 1326041450
$701.78
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $149 · 2021: $84.38.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $257.45 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $142.49 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $69.59 | 2019-2020 | |
| Amgen INC. | $58.89 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $33.35 | 2020 | |
| Horizon Therapeutics Plc | $32.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $18.60 | 2019 | |
| Shire North American Group INC | $16.72 | 2019 | |
| Opko Pharmaceuticals, LLC | $16.21 | 2019 | |
| Travere Therapeutics, INC. | $15.95 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.42 | 2020 | |
| Fresenius USA Marketing, INC. | $12.33 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $11.99 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Buchsbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.